157 / 172
157
adalimumab plus methotrexate in patients with rheumatoid
arthritis: ARMADA 4 year extended study. Ann Rheum Dis
2006;65:753-9.
107. Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O,
Smolen JS. Rheumatoid arthritis joint progression in sustained
remission is determined by disease activity levels preceding
the period of radiographic assessment. Arthritis Rheum
2009;60:1242-9.
108.Soubrier M, Lukas C, Sibilia J, Fautrel B, Roux F, Gossec L,
et al. Disease activity score-driven therapy versus routine care
in patients with recent-onset active rheumatoid arthritis: data
from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis
2011;70:611-5.
109.Möttönen T, Hannonen P, Leirisalo-Repo M, Nissilä M,
Kautiainen H, Korpela M, et al. Comparison of combination
therapy with single-drug therapy in early rheumatoid arthritis:
a randomised trial. FIN-RACo trial group. Lancet
1999;353:1568-73.
110.Möttönen T, Hannonen P, Korpela M, Nissilä M,
Kautiainen H, Ilonen J, et al. FINnish Rheumatoid Arthritis
Combination therapy. Delay to institution of therapy and
induction of remission using single-drug or combination-
disease-modifying antirheumatic drug therapy in early
rheumatoid arthritis. Arthritis Rheum 2002;46:894-8.
111.Puolakka K, Kautiainen H, Möttönen T, Hannonen P,
Korpela M, Hakala M, et al. Early suppression of disease
activity is essential for maintenance of work capacity in
patients with recent-onset rheumatoid arthritis: five-year
experience from the FIN-RACo trial. Arthritis Rheum
2005;52:36-41.
112.Rantalaiho V, Korpela M, Hannonen P, Kautiainen H,
Järvenpää S, Leirisalo-Repo M, et al. The good initial response
to therapy with a combination of traditional disease-
modifying antirheumatic drugs is sustained over time: the